Niclosamide, a drug used to treat tapeworms, has been approved as a potential treatment for COVID-19. ANA Therapeutics, a Silicon Valley-based biotech company, is poised to begin human clinical trials after receiving government approval under an investigational new drug application to treat COVID-19.
"ANA Therapeutics believes that Niclosamide has the strong potential to both stop viral replication and reduce symptoms in patients suffering from COVID-19," company officials stated in a press release, according to Fox News.
Niclosamide has been approved by the Food and Drug Administration to clear up tapeworm infections by killing worms on contact, according to the Mayo Clinic. Research recently revealed that the drug could also stop SARS-CoV-2, the virus that causes COVID-19, from replicating even more effectively than remdesivir. It's also a potent anti-inflammatory.
Akash Bakshi, the cofounder and CEO of ANA Therapeutics, said: "Anticipating that Niclosamide may prove to be effective against COVID-19, we are already laying plans to make the drug accessible to everyone," according to Fox News.
© 2021 NewsmaxHealth. All rights reserved.